BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang L, Han Y, Jiang Q, Wang C, Chen X, Li X, Xu F, Jiang Y, Wang Q, Xu W. Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy. Med Res Rev 2015;35:63-84. [PMID: 24782318 DOI: 10.1002/med.21320] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Wen J, Niu Q, Liu J, Bao Y, Yang J, Luan S, Fan Y, Liu D, Zhao L. Novel thiol-based histone deacetylase inhibitors bearing 3-phenyl-1 H -pyrazole-5-carboxamide scaffold as surface recognition motif: Design, synthesis and SAR study. Bioorganic & Medicinal Chemistry Letters 2016;26:375-9. [DOI: 10.1016/j.bmcl.2015.12.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
2 Yang L, Zhang W, Qiu Q, Su Z, Tang M, Bai P, Si W, Zhu Z, Liu Y, Yang J, Kuang S, Liu J, Yan W, Shi M, Ye H, Yang Z, Chen L. Discovery of a Series of Hydroxamic Acid-Based Microtubule Destabilizing Agents with Potent Antitumor Activity. J Med Chem 2021;64:15379-401. [PMID: 34648295 DOI: 10.1021/acs.jmedchem.1c01451] [Reference Citation Analysis]
3 Wang B, Chen X, Gao J, Su L, Zhang L, Xu H, Luan Y. Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors. Bioorganic & Medicinal Chemistry Letters 2019;29:2638-45. [DOI: 10.1016/j.bmcl.2019.07.045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
4 Osko JD, Christianson DW. Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6. Bioorg Med Chem Lett 2020;30:127023. [PMID: 32067866 DOI: 10.1016/j.bmcl.2020.127023] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
5 Bass AKA, Nageeb EM, El-Zoghbi MS, Mohamed MFA, Badr M, Abuo-Rahma GEA. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors. Bioorg Chem 2021;119:105564. [PMID: 34959179 DOI: 10.1016/j.bioorg.2021.105564] [Reference Citation Analysis]
6 Yu D, Kahen E, Cubitt CL, McGuire J, Kreahling J, Lee J, Altiok S, Lynch CC, Sullivan DM, Reed DR. Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma. Sci Rep 2015;5:16991. [PMID: 26601688 DOI: 10.1038/srep16991] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
7 Sun S, Zhao W, Li Y, Chi Z, Fang X, Wang Q, Han Z, Luan Y. Design, synthesis and antitumor activity evaluation of novel HDAC inhibitors with tetrahydrobenzothiazole as the skeleton. Bioorg Chem 2021;108:104652. [PMID: 33497873 DOI: 10.1016/j.bioorg.2021.104652] [Reference Citation Analysis]
8 Yang F, Zhang T, Wu H, Yang Y, Liu N, Chen A, Li Q, Li J, Qin L, Jiang B, Wang X, Pang X, Yi Z, Liu M, Chen Y. Design and Optimization of Novel Hydroxamate-Based Histone Deacetylase Inhibitors of Bis-Substituted Aromatic Amides Bearing Potent Activities against Tumor Growth and Metastasis. J Med Chem 2014;57:9357-69. [DOI: 10.1021/jm5012148] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
9 Abdizadeh R, Hadizadeh F, Abdizadeh T. QSAR analysis of coumarin-based benzamides as histone deacetylase inhibitors using CoMFA, CoMSIA and HQSAR methods. Journal of Molecular Structure 2020;1199:126961. [DOI: 10.1016/j.molstruc.2019.126961] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
10 Moses N, Zhang M, Wu JY, Hu C, Xiang S, Geng X, Chen Y, Bai W, Zhang YW, Bepler G, Zhang XM. HDAC6 Regulates Radiosensitivity of Non-Small Cell Lung Cancer by Promoting Degradation of Chk1. Cells 2020;9:E2237. [PMID: 33020410 DOI: 10.3390/cells9102237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
11 Lu D, Qu L, Wang C, Luo H, Li S, Yin F, Liu X, Chen X, Luo Z, Cui N, Peng W, Ji L, Kong L, Wang X. Harmine-based dual inhibitors targeting histone deacetylase (HDAC) and DNA as a promising strategy for cancer therapy. Bioorganic Chemistry 2022;120:105604. [DOI: 10.1016/j.bioorg.2022.105604] [Reference Citation Analysis]
12 Jänsch N, Meyners C, Muth M, Kopranovic A, Witt O, Oehme I, Meyer-Almes FJ. The enzyme activity of histone deacetylase 8 is modulated by a redox-switch. Redox Biol 2019;20:60-7. [PMID: 30292946 DOI: 10.1016/j.redox.2018.09.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
13 Meyners C, Krämer A, Yildiz Ö, Meyer-almes F. The thermodynamic signature of ligand binding to histone deacetylase-like amidohydrolases is most sensitive to the flexibility in the L2-loop lining the active site pocket. Biochimica et Biophysica Acta (BBA) - General Subjects 2017;1861:1855-63. [DOI: 10.1016/j.bbagen.2017.04.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
14 Was H, Krol SK, Rotili D, Mai A, Wojtas B, Kaminska B, Maleszewska M. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells. Clin Epigenetics 2019;11:11. [PMID: 30654849 DOI: 10.1186/s13148-018-0598-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
15 Fan W, Zhang L, Jiang Q, Song W, Yan F, Zhang L. Histone deacetylase inhibitor based prodrugs. Eur J Med Chem 2020;203:112628. [PMID: 32679451 DOI: 10.1016/j.ejmech.2020.112628] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
16 Uba AI, Yelekçi K. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay. J Biomol Struct Dyn 2018;36:3231-45. [PMID: 28938863 DOI: 10.1080/07391102.2017.1384402] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
17 Li Y, Wang F, Chen X, Wang J, Zhao Y, Li Y, He B. Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups. Curr Top Med Chem 2019;19:223-41. [PMID: 30674261 DOI: 10.2174/1568026619666190122144949] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
18 Yang F, Zhao N, Ge D, Chen Y. Next-generation of selective histone deacetylase inhibitors. RSC Adv 2019;9:19571-83. [DOI: 10.1039/c9ra02985k] [Cited by in Crossref: 33] [Article Influence: 11.0] [Reference Citation Analysis]
19 Micelli C, Rastelli G. Histone deacetylases: structural determinants of inhibitor selectivity. Drug Discov Today 2015;20:718-35. [PMID: 25687212 DOI: 10.1016/j.drudis.2015.01.007] [Cited by in Crossref: 109] [Cited by in F6Publishing: 93] [Article Influence: 15.6] [Reference Citation Analysis]
20 Ashrafizadeh M, Ahmadi Z, Samarghandian S, Mohammadinejad R, Yaribeygi H, Sathyapalan T, Sahebkar A. MicroRNA-mediated regulation of Nrf2 signaling pathway: Implications in disease therapy and protection against oxidative stress. Life Sci 2020;244:117329. [PMID: 31954747 DOI: 10.1016/j.lfs.2020.117329] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
21 Zhang S, Gong Y, Li C, Yang W, Li L. Beyond regulations at DNA levels: A review of epigenetic therapeutics targeting cancer stem cells. Cell Prolif 2021;54:e12963. [PMID: 33314500 DOI: 10.1111/cpr.12963] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Speed JS, Hyndman KA. In vivo organ specific drug delivery with implantable peristaltic pumps. Sci Rep 2016;6:26251. [PMID: 27185292 DOI: 10.1038/srep26251] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
23 Lipska K, Gumieniczek A, Filip AA. Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges. Acta Pharm 2020;70:291-301. [PMID: 32074065 DOI: 10.2478/acph-2020-0021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
24 Raji I, Yadudu F, Janeira E, Fathi S, Szymczak L, Kornacki JR, Komatsu K, Li JD, Mrksich M, Oyelere AK. Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase. Bioorg Med Chem 2017;25:1202-18. [PMID: 28057407 DOI: 10.1016/j.bmc.2016.12.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
25 Peng X, Sun Z, Kuang P, Chen J. Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment. European Journal of Medicinal Chemistry 2020;208:112831. [DOI: 10.1016/j.ejmech.2020.112831] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
26 Xiang XS, Li PC, Wang WQ, Liu L. Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer. Biochim Biophys Acta Rev Cancer 2022;1877:188676. [PMID: 35016922 DOI: 10.1016/j.bbcan.2022.188676] [Reference Citation Analysis]
27 Good KV, Martínez de Paz A, Tyagi M, Cheema MS, Thambirajah AA, Gretzinger TL, Stefanelli G, Chow RL, Krupke O, Hendzel M, Missiaen K, Underhill A, Landsberger N, Ausió J. Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding affinity. Epigenetics 2017;12:934-44. [PMID: 29099289 DOI: 10.1080/15592294.2017.1380760] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
28 Ling Y, Xu C, Luo L, Cao J, Feng J, Xue Y, Zhu Q, Ju C, Li F, Zhang Y, Zhang Y, Ling X. Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway. J Med Chem 2015;58:9214-27. [PMID: 26555243 DOI: 10.1021/acs.jmedchem.5b01052] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
29 Wang X, Li X, Li J, Hou J, Qu Y, Yu C, He F, Xu W, Wu J. Design, synthesis, and preliminary bioactivity evaluation of N1 -hydroxyterephthalamide derivatives with indole cap as novel histone deacetylase inhibitors. Chem Biol Drug Des 2017;89:38-46. [DOI: 10.1111/cbdd.12819] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
30 Fan W, Zhang L, Wang X, Jia H, Zhang L. Discovery of potent histone deacetylase inhibitors with modified phenanthridine caps. J Enzyme Inhib Med Chem 2021;36:707-18. [PMID: 33663315 DOI: 10.1080/14756366.2021.1892089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Ibrahim TS, Malebari AM, Mohamed MFA. Design, Synthesis, In Vitro Anticancer Evaluation and Molecular Modelling Studies of 3,4,5-Trimethoxyphenyl-Based Derivatives as Dual EGFR/HDAC Hybrid Inhibitors. Pharmaceuticals (Basel) 2021;14:1177. [PMID: 34832959 DOI: 10.3390/ph14111177] [Reference Citation Analysis]
32 Narita K, Matsuhara K, Itoh J, Akiyama Y, Dan S, Yamori T, Ito A, Yoshida M, Katoh T. Synthesis and biological evaluation of novel FK228 analogues as potential isoform selective HDAC inhibitors. European Journal of Medicinal Chemistry 2016;121:592-609. [DOI: 10.1016/j.ejmech.2016.05.031] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
33 Hafez DA, Hassanin IA, Teleb M, Khattab SN, Elkhodairy KA, Elzoghby AO. Recent advances in nanomedicine-based delivery of histone deacetylase inhibitors for cancer therapy. Nanomedicine (Lond) 2021;16:2305-25. [PMID: 34551585 DOI: 10.2217/nnm-2021-0196] [Reference Citation Analysis]
34 Sun HJ, Chen J, Ni B, Yang X, Wu YZ. Recent advances and current issues in single-cell sequencing of tumors. Cancer Lett 2015;365:1-10. [PMID: 26003306 DOI: 10.1016/j.canlet.2015.04.022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
35 Chen Y, Zhang L, Zhang L, Jiang Q, Zhang L. Discovery of indole-3-butyric acid derivatives as potent histone deacetylase inhibitors. J Enzyme Inhib Med Chem 2021;36:425-36. [PMID: 33445997 DOI: 10.1080/14756366.2020.1870457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Thakur A, Tawa GJ, Henderson MJ, Danchik C, Liu S, Shah P, Wang AQ, Dunn G, Kabir M, Padilha EC, Xu X, Simeonov A, Kharbanda S, Stone R, Grewal G. Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. J Med Chem 2020;63:4256-92. [PMID: 32212730 DOI: 10.1021/acs.jmedchem.0c00193] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
37 Zhou M, Yuan M, Zhang M, Lei C, Aras O, Zhang X, An F. Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy. Eur J Med Chem 2021;226:113825. [PMID: 34562854 DOI: 10.1016/j.ejmech.2021.113825] [Reference Citation Analysis]
38 Luo G, Lin X, Ren S, Wu S, Wang X, Ma L, Xiang H. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer. Eur J Med Chem 2021;226:113870. [PMID: 34610548 DOI: 10.1016/j.ejmech.2021.113870] [Reference Citation Analysis]
39 Zhang L, Chen Y, Jiang Q, Song W, Zhang L. Therapeutic potential of selective histone deacetylase 3 inhibition. Eur J Med Chem 2019;162:534-42. [PMID: 30472601 DOI: 10.1016/j.ejmech.2018.10.072] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
40 Gunia-Krzyżak A, Pańczyk K, Waszkielewicz AM, Marona H. Cinnamamide Derivatives for Central and Peripheral Nervous System Disorders--A Review of Structure-Activity Relationships. ChemMedChem 2015;10:1302-25. [PMID: 26083325 DOI: 10.1002/cmdc.201500153] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
41 Wang F, Wang C, Wang J, Zou Y, Chen X, Liu T, Li Y, Zhao Y, Li Y, He B. N ɛ -acetyl lysine derivatives with zinc binding groups as novel HDAC inhibitors. R Soc Open Sci 2019;6:190338. [PMID: 31312496 DOI: 10.1098/rsos.190338] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
42 Halder AK, Mallick S, Shikha D, Saha A, Saha KD, Jha T. Design of dual MMP-2/HDAC-8 inhibitors by pharmacophore mapping, molecular docking, synthesis and biological activity. RSC Adv 2015;5:72373-86. [DOI: 10.1039/c5ra12606a] [Cited by in Crossref: 37] [Article Influence: 5.3] [Reference Citation Analysis]
43 Chan AM, Fletcher S. Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6. RSC Med Chem 2021;12:178-96. [PMID: 34046608 DOI: 10.1039/d0md00286k] [Reference Citation Analysis]
44 Miao J, Meng C, Wu H, Shan W, Wang H, Ling C, Zhang J, Yang T. Novel Hybrid CHC from β-carboline and N-Hydroxyacrylamide Overcomes Drug-Resistant Hepatocellular Carcinoma by Promoting Apoptosis, DNA Damage, and Cell Cycle Arrest. Front Pharmacol 2020;11:626065. [PMID: 33536926 DOI: 10.3389/fphar.2020.626065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Laschanzky RS, Humphrey LE, Ma J, Smith LM, Enke TJ, Shukla SK, Dasgupta A, Singh PK, Howell GM, Brattain MG, Ly QP, Black AR, Black JD. Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy. Cancers (Basel) 2019;11:E1327. [PMID: 31500290 DOI: 10.3390/cancers11091327] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
46 Dzinic SH, Chen K, Thakur A, Kaplun A, Bonfil RD, Li X, Liu J, Bernardo MM, Saliganan A, Back JB, Yano H, Schalk DL, Tomaszewski EN, Beydoun AS, Dyson G, Mujagic A, Krass D, Dean I, Mi QS, Heath E, Sakr W, Lum LG, Sheng S. Maspin expression in prostate tumor elicits host anti-tumor immunity. Oncotarget. 2014;5:11225-11236. [PMID: 25373490 DOI: 10.18632/oncotarget.2615] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
47 Sirous H, Campiani G, Brogi S, Calderone V, Chemi G. Computer-Driven Development of an in Silico Tool for Finding Selective Histone Deacetylase 1 Inhibitors. Molecules 2020;25:E1952. [PMID: 32331470 DOI: 10.3390/molecules25081952] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
48 Pham-the H, Casañola-martin G, Diéguez-santana K, Nguyen-hai N, Ngoc N, Vu-duc L, Le-thi-thu H. Quantitative structure–activity relationship analysis and virtual screening studies for identifying HDAC2 inhibitors from known HDAC bioactive chemical libraries. SAR and QSAR in Environmental Research 2017;28:199-220. [DOI: 10.1080/1062936x.2017.1294198] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.6] [Reference Citation Analysis]
49 Zwergel C, Valente S, Jacob C, Mai A. Emerging approaches for histone deacetylase inhibitor drug discovery. Expert Opinion on Drug Discovery 2015;10:599-613. [DOI: 10.1517/17460441.2015.1038236] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
50 Li G, Lou HX. Strategies to diversify natural products for drug discovery. Med Res Rev 2018;38:1255-94. [PMID: 29064108 DOI: 10.1002/med.21474] [Cited by in Crossref: 89] [Cited by in F6Publishing: 75] [Article Influence: 17.8] [Reference Citation Analysis]
51 Yuan Z, Chen S, Sun Q, Wang N, Li D, Miao S, Gao C, Chen Y, Tan C, Jiang Y. Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy. Bioorganic & Medicinal Chemistry 2017;25:4100-9. [DOI: 10.1016/j.bmc.2017.05.058] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
52 Hennig D, Imhof D. Encapsulation of the HDACi Ex527 into Liposomes and Polymer-Based Particles. Methods Mol Biol 2017;1510:387-98. [PMID: 27761837 DOI: 10.1007/978-1-4939-6527-4_29] [Reference Citation Analysis]
53 Tan Y, Zhang S, Zhu H, Chu Y, Zhou H, Liu D, Huo J. Histone deacetylase 6 selective inhibitor ACY1215 inhibits cell proliferation and enhances the chemotherapeutic effect of 5-fluorouracil in HCT116 cells. Ann Transl Med 2019;7:2. [PMID: 30788349 DOI: 10.21037/atm.2018.11.48] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
54 Hou X, Du J, Liu R, Zhou Y, Li M, Xu W, Fang H. Enhancing the Sensitivity of Pharmacophore-Based Virtual Screening by Incorporating Customized ZBG Features: A Case Study Using Histone Deacetylase 8. J Chem Inf Model 2015;55:861-71. [DOI: 10.1021/ci500762z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
55 Zhang L, Li X, Chen Y, Wan M, Jiang Q, Zhang L, Chou CJ, Song W, Zhang L. Discovery of N-(2-Aminophenyl)-4-(bis(2-chloroethyl)amino)Benzamide as a Potent Histone Deacetylase Inhibitor. Front Pharmacol 2019;10:957. [PMID: 31543818 DOI: 10.3389/fphar.2019.00957] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Feng S, Wang H, Liu J, Aa J, Zhou F, Wang G. Multi-dimensional roles of ketone bodies in cancer biology: Opportunities for cancer therapy. Pharmacol Res 2019;150:104500. [PMID: 31629092 DOI: 10.1016/j.phrs.2019.104500] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
57 Chen Y, Feng J, Hu Y, Wang X, Song W, Zhang L. Discovery of N-(2-Amino-4-Fluorophenyl)-4-[bis-(2-Chloroethyl)-Amino]-Benzamide as a Potent HDAC3 Inhibitor. Front Oncol 2020;10:592385. [PMID: 33178617 DOI: 10.3389/fonc.2020.592385] [Reference Citation Analysis]
58 Tavares MT, de Almeida LC, Kronenberger T, Monteiro Ferreira G, Fujii de Divitiis T, Franco Zannini Junqueira Toledo M, Mariko Aymoto Hassimotto N, Agostinho Machado-Neto J, Veras Costa-Lotufo L, Parise-Filho R. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors. Bioorg Med Chem 2021;35:116085. [PMID: 33668008 DOI: 10.1016/j.bmc.2021.116085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Deng R, Zhang P, Liu W, Zeng X, Ma X, Shi L, Wang T, Yin Y, Chang W, Zhang P, Wang G, Tao K. HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer. Clin Epigenetics 2018;10:153. [PMID: 30537988 DOI: 10.1186/s13148-018-0589-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
60 Sun W, Yi Y, Xia G, Zhao Y, Yu Y, Li L, Hua C, He B, Yang B, Yu C, Ye C, Tu F, Chen C, Xu X, Zheng Z, Wang W, Shen X. Nrf2-miR-129-3p-mTOR Axis Controls an miRNA Regulatory Network Involved in HDACi-Induced Autophagy. Mol Ther 2019;27:1039-50. [PMID: 30852137 DOI: 10.1016/j.ymthe.2019.02.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
61 Zhang L, Zhang L, Bian J, Jiang Q, Gao J, Song W. Structural modification of histone deacetylase inhibitors with a phenylglycine scaffold. Anticancer Drugs 2018;29:145-56. [PMID: 33052636 DOI: 10.1097/CAD.0000000000000579] [Reference Citation Analysis]
62 Jiao P, Jin P, Li C, Cui L, Dong L, Pan B, Song W, Ma L, Dong J, Song L, Jin X, Li F, Wan M, Lv Z, Geng Q. Design, synthesis and in vitro evaluation of amidoximes as histone deacetylase inhibitors for cancer therapy. Bioorg Med Chem Lett 2016;26:4679-83. [PMID: 27597246 DOI: 10.1016/j.bmcl.2016.08.073] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
63 Ling Y, Wang X, Wang C, Xu C, Zhang W, Zhang Y, Zhang Y. Hybrids from Farnesylthiosalicylic Acid and Hydroxamic Acid as Dual Ras-Related Signaling and Histone Deacetylase (HDAC) Inhibitors: Design, Synthesis and Biological Evaluation. ChemMedChem 2015;10:971-6. [PMID: 25882299 DOI: 10.1002/cmdc.201500019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
64 Luan Y, Li J, Bernatchez JA, Li R. Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy. J Med Chem 2019;62:3171-83. [PMID: 30418766 DOI: 10.1021/acs.jmedchem.8b00189] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 14.5] [Reference Citation Analysis]
65 Frère A, Baroni A, Hendrick E, Delvigne A, Orange F, Peulen O, Dakwar GR, Diricq J, Dubois P, Evrard B, Remaut K, Braeckmans K, De Smedt SC, Laloy J, Dogné J, Feller G, Mespouille L, Mottet D, Piel G. PEGylated and Functionalized Aliphatic Polycarbonate Polyplex Nanoparticles for Intravenous Administration of HDAC5 siRNA in Cancer Therapy. ACS Appl Mater Interfaces 2017;9:2181-95. [DOI: 10.1021/acsami.6b15064] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
66 Yang F, Han L, Zhao N, Yang Y, Ge D, Zhang H, Chen Y. Synthesis and biological evaluation of thiophene-based hydroxamate derivatives as HDACis with antitumor activities. Future Med Chem 2020;12:655-72. [PMID: 32202140 DOI: 10.4155/fmc-2019-0343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Xiao Y, Wang J, Zhao LY, Chen X, Zheng G, Zhang X, Liao D. Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs. Chem Commun (Camb) 2020;56:9866-9. [PMID: 32840532 DOI: 10.1039/d0cc03243c] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 11.0] [Reference Citation Analysis]
68 Zhang L, Zhang J, Jiang Q, Zhang L, Song W. Zinc binding groups for histone deacetylase inhibitors. J Enzyme Inhib Med Chem 2018;33:714-21. [PMID: 29616828 DOI: 10.1080/14756366.2017.1417274] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 15.8] [Reference Citation Analysis]
69 Gediya P, Parikh PK, Vyas VK, Ghate MD. Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders. Eur J Med Chem 2021;216:113332. [PMID: 33714914 DOI: 10.1016/j.ejmech.2021.113332] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]